Luisa Quinti

1.9k total citations
25 papers, 1.3k citations indexed

About

Luisa Quinti is a scholar working on Physiology, Molecular Biology and Neurology. According to data from OpenAlex, Luisa Quinti has authored 25 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Physiology, 8 papers in Molecular Biology and 7 papers in Neurology. Recurrent topics in Luisa Quinti's work include Alzheimer's disease research and treatments (7 papers), Sirtuins and Resveratrol in Medicine (6 papers) and Neuroinflammation and Neurodegeneration Mechanisms (6 papers). Luisa Quinti is often cited by papers focused on Alzheimer's disease research and treatments (7 papers), Sirtuins and Resveratrol in Medicine (6 papers) and Neuroinflammation and Neurodegeneration Mechanisms (6 papers). Luisa Quinti collaborates with scholars based in United States, Jordan and Germany. Luisa Quinti's co-authors include Ching‐Hsuan Tung, Ralph Weissleder, Aleksey Kazantsev, Vanita Chopra, Steven M. Hersch, Rudolph E. Tanzi, Richard B. Silverman, Doo Yeon Kim, Se Hoon Choi and Farouc A. Jaffer and has published in prestigious journals such as Circulation, Neuron and Nano Letters.

In The Last Decade

Luisa Quinti

24 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luisa Quinti United States 15 548 328 295 192 175 25 1.3k
Roberta Felici Italy 16 534 1.0× 302 0.9× 136 0.5× 148 0.8× 59 0.3× 18 1.1k
Andrea Lapucci Italy 24 1.1k 1.9× 198 0.6× 172 0.6× 144 0.8× 78 0.4× 54 1.7k
Michael Coronado United States 9 576 1.1× 68 0.2× 114 0.4× 103 0.5× 109 0.6× 12 1.2k
Elena Rapizzi Italy 25 1.4k 2.6× 158 0.5× 261 0.9× 291 1.5× 181 1.0× 61 2.5k
Anja Apel Germany 12 569 1.0× 42 0.1× 196 0.7× 487 2.5× 89 0.5× 17 1.3k
Laura Emionite Italy 29 1.2k 2.2× 85 0.3× 476 1.6× 173 0.9× 90 0.5× 74 2.6k
Lorraine Morlock United States 17 583 1.1× 73 0.2× 148 0.5× 89 0.5× 155 0.9× 18 1.0k
Ye Zhou United States 12 296 0.5× 140 0.4× 230 0.8× 129 0.7× 125 0.7× 19 872
Benjamin Gottschalk Austria 22 924 1.7× 51 0.2× 285 1.0× 119 0.6× 169 1.0× 57 1.3k
Liya Yuan United States 19 632 1.2× 41 0.1× 97 0.3× 96 0.5× 83 0.5× 34 1.6k

Countries citing papers authored by Luisa Quinti

Since Specialization
Citations

This map shows the geographic impact of Luisa Quinti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luisa Quinti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luisa Quinti more than expected).

Fields of papers citing papers by Luisa Quinti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luisa Quinti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luisa Quinti. The network helps show where Luisa Quinti may publish in the future.

Co-authorship network of co-authors of Luisa Quinti

This figure shows the co-authorship network connecting the top 25 collaborators of Luisa Quinti. A scholar is included among the top collaborators of Luisa Quinti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luisa Quinti. Luisa Quinti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Piłat, Dominika, Dmitry Prokopenko, Chih‐Chung Lin, et al.. (2025). The gain-of-function TREM2-T96K mutation increases risk for Alzheimer’s disease by impairing microglial function. Neuron. 114(1). 46–66.e13.
2.
Yeganeh, Pourya Naderi, Mehdi Jorfi, Djuna von Maydell, et al.. (2024). Integrative pathway analysis across humans and 3D cellular models identifies the p38 MAPK-MK2 axis as a therapeutic target for Alzheimer’s disease. Neuron. 113(2). 205–224.e8. 8 indexed citations
3.
Podvin, Sonia, Barry Greenberg, Jeremiah D. Momper, et al.. (2023). Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease. Frontiers in Pharmacology. 14. 1190402–1190402. 12 indexed citations
4.
Kim, Eunhee, Hyeonwoo Kim, Mark P. Jedrychowski, et al.. (2023). Irisin reduces amyloid-β by inducing the release of neprilysin from astrocytes following downregulation of ERK-STAT3 signaling. Neuron. 111(22). 3619–3633.e8. 58 indexed citations
5.
Liang, Yingxia, David Y.W. Lee, Haoqi Sun, et al.. (2022). Natural medicine HLXL targets multiple pathways of amyloid-mediated neuroinflammation and immune response in treating alzheimer's disease. Phytomedicine. 104. 154158–154158. 7 indexed citations
6.
Shoup, Timothy M., Marc D. Normandin, Kazue Takahashi, et al.. (2019). Fluorinated Cromolyn Derivatives for Potential Alzheimer’s Disease Treatment. 60. 114–114. 1 indexed citations
7.
Zhang, Can, Ana Griciuc, Eloïse Hudry, et al.. (2018). Cromolyn Reduces Levels of the Alzheimer’s Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis. Scientific Reports. 8(1). 1144–1144. 72 indexed citations
8.
Quinti, Luisa, et al.. (2017). [P4–404]: A NOVEL DRUG‐SCREENING PLATFORM IN MICROGLIAL CELLS IDENTIFIES POTENTIAL AD DRUGS. Alzheimer s & Dementia. 13(7S_Part_31). 2 indexed citations
9.
Wagner, Steven L., Kevin D. Rynearson, Steven K. Duddy, et al.. (2017). Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606. Journal of Pharmacology and Experimental Therapeutics. 362(1). 31–44. 35 indexed citations
10.
Choi, Se Hoon, Young Hye Kim, Luisa Quinti, Rudolph E. Tanzi, & Doo Yeon Kim. (2016). 3D culture models of Alzheimer’s disease: a road map to a “cure-in-a-dish”. Molecular Neurodegeneration. 11(1). 75–75. 102 indexed citations
11.
Chopra, Vanita, Luisa Quinti, Paolo Paganetti, et al.. (2016). LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington’s Disease. Journal of Huntington s Disease. 5(4). 347–355. 27 indexed citations
12.
Wales, Pauline, Luisa Quinti, Fuxing Zuo, et al.. (2015). The Sirtuin-2 Inhibitor AK7 Is Neuroprotective in Models of Parkinson’s Disease but Not Amyotrophic Lateral Sclerosis and Cerebral Ischemia. PLoS ONE. 10(1). e0116919–e0116919. 104 indexed citations
13.
Khanfar, Mohammad A., Luisa Quinti, Hua Wang, et al.. (2014). Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors. European Journal of Medicinal Chemistry. 76. 414–426. 27 indexed citations
14.
Choi, Soo Hyuk, Luisa Quinti, Aleksey Kazantsev, & Richard B. Silverman. (2012). 3-(N-Arylsulfamoyl)benzamides, inhibitors of human sirtuin type 2 (SIRT2). Bioorganic & Medicinal Chemistry Letters. 22(8). 2789–2793. 14 indexed citations
15.
Chopra, Vanita, Luisa Quinti, Jinho Kim, et al.. (2012). The Sirtuin 2 Inhibitor AK-7 Is Neuroprotective in Huntington’s Disease Mouse Models. Cell Reports. 2(6). 1492–1497. 166 indexed citations
16.
Maxwell, Michele M., John Wizeman, Allison Amore, et al.. (2011). The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Human Molecular Genetics. 20(20). 3986–3996. 166 indexed citations
17.
18.
Kozloff, Kenneth M., Luisa Quinti, Somying Patntirapong, et al.. (2008). Non-invasive optical detection of cathepsin K-mediated fluorescence reveals osteoclast activity in vitro and in vivo. Bone. 44(2). 190–198. 62 indexed citations
19.
Quinti, Luisa, et al.. (2007). Non-invasive imaging of osteoclast activity via near-infrared cathepsin-K activatable optical probe.. PubMed. 6(4). 353–353. 3 indexed citations
20.
Law, Benedict, Luisa Quinti, Yongdoo Choi, Ralph Weissleder, & Ching‐Hsuan Tung. (2006). A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity. Molecular Cancer Therapeutics. 5(8). 1944–1949. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roberta Felici Breakdown of academic impact, for papers by Andrea Lapucci Breakdown of academic impact, for papers by Michael Coronado Breakdown of academic impact, for papers by Elena Rapizzi Breakdown of academic impact, for papers by Anja Apel Breakdown of academic impact, for papers by Laura Emionite Breakdown of academic impact, for papers by Lorraine Morlock Breakdown of academic impact, for papers by Ye Zhou Breakdown of academic impact, for papers by Benjamin Gottschalk Breakdown of academic impact, for papers by Liya Yuan
Rankless by CCL
2026